文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

比利时2021年7月至2022年5月COVID-19疫苗对症状性感染和住院的有效性

COVID-19 vaccine effectiveness against symptomatic infection and hospitalisation in Belgium, July 2021 to May 2022.
PubMed 文献 · Euro Surveill · 2023-01-01

比利时全国检测与疫苗接种记录结合医院临床调查,采用检测阴性设计和比例风险回归,估计SARS-CoV-2变异特异性疫苗对症状性感染(VEi)和住院(VEh)的有效性,并考虑接种时间和既往感染。结果显示VEi和VEh随时间衰减,从Delta到Omicron优势期显著下降,加强接种和既往感染可减弱这些效应。

要点

  • Delta期VEi从80%降至100-150天后55%,加强接种后初始VEi升至85%。
  • Omicron期初始VEi为33%,加强后升至50%,100-150天后降至20%。
  • 加强接种对Delta住院VEh从96%降至Omicron的87%,Omicron期100-150天后VEh为73%。

核心结论

  • 报告VEi和VEh随时间衰减,且从Delta到Omicron优势期显著下降。
  • 加强接种和既往感染可减弱这些效应。

研究设计与样本

  • 全国性医疗记录(2021年7月至2022年5月)结合医院临床调查的检测阴性设计。
  • 纳入1,932,546名有症状个体,其中734,115人检测阳性。
  • 采用比例风险回归估计VEi和VEh,控制既往感染、接种时间、年龄、性别、居住地和采样日历周。

主要发现

  • Delta期VEi从初始80%(95%CI:80-81)降至初免后100-150天的55%(95%CI:54-55)。
  • 加强接种后初始VEi升至85%(95%CI:84-85)。
  • Omicron期初始VEi为33%(95%CI:30-36),降至17%(95%CI:15-18);加强后升至50%(95%CI:49-50),接种后100-150天降至20%(95%CI:19-21)。
  • 加强接种的初始VEh对Delta为96%(95%CI:95-96),对Omicron为87%(95%CI:86-89);Omicron期加强后100-150天VEh降至73%(95%CI:71-75)。
  • 近期既往感染提供更高保护,2021年前的感染仍与症状性感染风险显著降低相关;接种和既往感染优于仅接种或仅既往感染。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BackgroundThe Belgian COVID-19 vaccination campaign aimed to reduce disease spread and severity.AimWe estimated SARS-CoV-2 variant-specific vaccine effectiveness against symptomatic infection (VEi) and hospitalisation (VEh), given time since vaccination and prior infection.MethodsNationwide healthcare records from July 2021 to May 2022 on testing and vaccination were combined with a clinical hospital survey. We used a test-negative design and proportional hazard regression to estimate VEi and VEh, controlling for prior infection, time since vaccination, age, sex, residence and calendar week of sampling.ResultsWe included 1,932,546 symptomatic individuals, of whom 734,115 tested positive. VEi against Delta waned from an initial estimate of 80% (95% confidence interval (CI): 80-81) to 55% (95% CI: 54-55) 100-150 days after the primary vaccination course. Booster vaccination increased initial VEi to 85% (95% CI: 84-85). Against Omicron, an initial VEi of 33% (95% CI: 30-36) waned to 17% (95% CI: 15-18), while booster vaccination increased VEi to 50% (95% CI: 49-50), which waned to 20% (95% CI: 19-21) 100-150 days after vaccination. Initial VEh for booster vaccination decreased from 96% (95% CI: 95-96) against Delta to 87% (95% CI: 86-89) against Omicron. VEh against Omicron waned to 73% (95% CI: 71-75) 100-150 days after booster vaccination. While recent prior infections conferred higher protection, infections occurring before 2021 remained associated with significant risk reduction against symptomatic infection. Vaccination and prior infection outperformed vaccination or prior infection only.ConclusionWe report waning and a significant decrease in VEi and VEh from Delta to Omicron-dominant periods. Booster vaccination and prior infection attenuated these effects.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. Braeye T, van Loenhout JAF, Brondeel R, et al. COVID-19 vaccine effectiveness against symptomatic infection and hospitalisation in Belgium, July 2021 to May 2022. Euro Surveill. 2023. PMID: 37382885. doi:10.2807/1560-7917.ES.2023.28.26.2200768

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。